Sarah Winawer-Wetzel, MBA, FACHE
@sarahwinwetz.bsky.social
110 followers
190 following
21 posts
📌 Now: Strategy & Ops at @pc3innovation.bsky.social
🏢 Past: @danafarber.bsky.social, Penn Medicine Palliative Care
🎓 BA @smith-college.bsky.social
🎓 MBA @brandeisuniversity.bsky.social
🌈 she/her | all posts are my own
Posts
Media
Videos
Starter Packs
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
The Cancer Letter
@cancerletter.com
· Jul 29
Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care? - The Cancer Letter
On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]
cancerletter.com
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
The Cancer Letter
@cancerletter.com
· May 22
Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges...
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan. To access this […]
cancerletter.com
The Cancer Letter
@cancerletter.com
· May 12
Trump administration is removing the mainstays of NCI and the federal government’s cancer program Peer review, registries, and evidence-based patient information take a big hit - The Cancer Letter
How is the enterprise of cancer research doing after the first 100 days of the Trump administration? To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
cancerletter.com
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
The Cancer Letter
@cancerletter.com
· Mar 24
Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages - The Cancer Letter
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink. To access this subscriber-only content please log in or subscribe.If your institution has a […]
cancerletter.com
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
The Cancer Letter
@cancerletter.com
· Mar 25
Caught in the crossfire: The critical threats facing cancer centers, research, and patient care - The Cancer Letter
NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment. Funding instability, including freezes on federal grants and sudden cuts to indirect cost rates, is creating a ripple effect that disrupts the entire cancer […]
cancerletter.com
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE
Reposted by Sarah Winawer-Wetzel, MBA, FACHE